These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study. Nougué H; Pezel T; Picard F; Sadoune M; Arrigo M; Beauvais F; Launay JM; Cohen-Solal A; Vodovar N; Logeart D Eur J Heart Fail; 2019 May; 21(5):598-605. PubMed ID: 30520545 [TBL] [Abstract][Full Text] [Related]
4. Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan. Liu RC Am J Cardiovasc Drugs; 2018 Dec; 18(6):473-482. PubMed ID: 29850980 [TBL] [Abstract][Full Text] [Related]
5. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck. Ansara AJ; Kolanczyk DM; Koehler JM J Clin Pharm Ther; 2016 Apr; 41(2):119-27. PubMed ID: 26992459 [TBL] [Abstract][Full Text] [Related]
6. The Rationale of Neprilysin Inhibition in Prevention of Myocardial Ischemia-Reperfusion Injury during ST-Elevation Myocardial Infarction. Bellis A; Mauro C; Barbato E; Di Gioia G; Sorriento D; Trimarco B; Morisco C Cells; 2020 Sep; 9(9):. PubMed ID: 32967374 [TBL] [Abstract][Full Text] [Related]
7. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Jhund PS; McMurray JJ Heart; 2016 Sep; 102(17):1342-7. PubMed ID: 27207980 [TBL] [Abstract][Full Text] [Related]
8. Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM. Lillyblad MP Ann Pharmacother; 2015 Nov; 49(11):1237-51. PubMed ID: 26175499 [TBL] [Abstract][Full Text] [Related]
9. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. McMurray JJ Eur J Heart Fail; 2015 Mar; 17(3):242-7. PubMed ID: 25756942 [TBL] [Abstract][Full Text] [Related]
10. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936 [TBL] [Abstract][Full Text] [Related]
11. The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-β concentrations and clearance in the cynomolgus monkey. Schoenfeld HA; West T; Verghese PB; Holubasch M; Shenoy N; Kagan D; Buono C; Zhou W; DeCristofaro M; Douville J; Goodrich GG; Mansfield K; Saravanan C; Cumin F; Webb RL; Bateman RJ Toxicol Appl Pharmacol; 2017 May; 323():53-65. PubMed ID: 28315356 [TBL] [Abstract][Full Text] [Related]
12. Sacubitril/valsartan in COVID-19 patients: the need for trials. Acanfora D; Ciccone MM; Scicchitano P; Acanfora C; Casucci G Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):253-254. PubMed ID: 32369103 [No Abstract] [Full Text] [Related]
13. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP; N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794 [TBL] [Abstract][Full Text] [Related]